ArticlePreventive medicine reports2025
Associations between klotho levels and mortality risk among middle-aged and older adults taking prescription opioids.
Article in Preventive medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Prescription opioids are widely recognized as the most commonly used and effective analgesics for the management of moderate to severe pain. Klotho protein has been indicated to show a nonlinear relationship with mortality, but findings are inconsistent across populations. The present study investigated the association between Klotho levels and mortality in middle-aged and older adults who use prescription opioids, with the aim of identifying potential therapeutic targets. Methods: This study included participants aged ≥40 years from the National Health and Nutrition Examination Survey (2007-2018) with complete data. Mortality data were obtained from the 2019 public use-linked mortality files released by the National Center for Health Statistics in May 2022. Covariates included demographics, lifestyle habits, and disease history. Survey-weighted Cox regression assessed the relationship between Klotho levels and mortality risk. Results: Among the 898 participants (mean age 56 years; 43.3 % men) followed up for a median of 88 months, 13.5 % died. Participants in the third Klotho quartile had a lower risk of all-cause mortality compared to the first quartile. Higher Klotho levels were associated with lower cancer mortality, but cardiovascular mortality did not differ significantly. Restricted cubic spline analysis revealed a significant nonlinear association between Klotho levels and all-cause mortality (nonlinear Conclusions: A significant nonlinear relationship exists between Klotho levels and all-cause mortality among middle-aged and older adults taking prescription opioids. Future research should explore mechanisms underlying this relationship and develop Klotho-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.